246 related articles for article (PubMed ID: 33054787)
21. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin.
Pettibone DJ; Hess JF; Hey PJ; Jacobson MA; Leviten M; Lis EV; Mallorga PJ; Pascarella DM; Snyder MA; Williams JB; Zeng Z
J Pharmacol Exp Ther; 2002 Jan; 300(1):305-13. PubMed ID: 11752130
[TBL] [Abstract][Full Text] [Related]
22. Passive and receptor mediated brain delivery of an anti-GFAP nanobody.
Meier SR; Sehlin D; Syvänen S
Nucl Med Biol; 2022; 114-115():121-127. PubMed ID: 35487832
[TBL] [Abstract][Full Text] [Related]
23. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J
J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574
[TBL] [Abstract][Full Text] [Related]
24. Applications of nanobodies in brain diseases.
Zheng F; Pang Y; Li L; Pang Y; Zhang J; Wang X; Raes G
Front Immunol; 2022; 13():978513. PubMed ID: 36426363
[TBL] [Abstract][Full Text] [Related]
25. Adaptation to cold antagonizes neurotensin-induced hypothermia in mice.
Merritt WD; Bissette G; Luttinger D; Prange AJ; Nemeroff CB
Brain Res; 1986 Mar; 369(1-2):136-42. PubMed ID: 3697737
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys.
Fantegrossi WE; Ko MC; Woods JH; Richelson E
Pharmacol Biochem Behav; 2005 Feb; 80(2):341-9. PubMed ID: 15680187
[TBL] [Abstract][Full Text] [Related]
27. Comparison of neurotensin levels, receptors and actions in LS/Ibg and SS/Ibg mice.
Erwin VG; Jones BC
Peptides; 1989; 10(2):435-40. PubMed ID: 2547208
[TBL] [Abstract][Full Text] [Related]
28. The 46.1 Antibody Mediates Neurotensin Uptake into the CNS and the Effects Depend on the Route of Intravenous Administration.
Georgieva JV; Katt M; Ye Z; Umlauf BJ; Wenthur CJ; Shusta EV
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015332
[TBL] [Abstract][Full Text] [Related]
29. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells.
Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G
Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371
[TBL] [Abstract][Full Text] [Related]
30. Tolerance to the hypothermic but not to the analgesic effect of [D-Trp11]neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats.
Dubuc I; Pain C; Suaudeau C; Costentin J
Peptides; 1994; 15(2):303-7. PubMed ID: 8008636
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
[TBL] [Abstract][Full Text] [Related]
32. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.
Edavettal S; Cejudo-Martin P; Dasgupta B; Yang D; Buschman MD; Domingo D; Van Kolen K; Jaiprasat P; Gordon R; Schutsky K; Geist B; Taylor N; Soubrane CH; Van Der Helm E; LaCombe A; Ainekulu Z; Lacy E; Aligo J; Ho J; He Y; Lebowitz PF; Patterson JT; Scheer JM; Singh S
Med; 2022 Dec; 3(12):860-882.e15. PubMed ID: 36257298
[TBL] [Abstract][Full Text] [Related]
33. Identification of the receptor subtype involved in the analgesic effect of neurotensin.
Dubuc I; Sarret P; Labbé-Jullié C; Botto JM; Honoré E; Bourdel E; Martinez J; Costentin J; Vincent JP; Kitabgi P; Mazella J
J Neurosci; 1999 Jan; 19(1):503-10. PubMed ID: 9870978
[TBL] [Abstract][Full Text] [Related]
34. Transferrin receptor expression and role in transendothelial transport of transferrin in cultured brain endothelial monolayers.
Hersom M; Helms HC; Pretzer N; Goldeman C; Jensen AI; Severin G; Nielsen MS; Holm R; Brodin B
Mol Cell Neurosci; 2016 Oct; 76():59-67. PubMed ID: 27567687
[TBL] [Abstract][Full Text] [Related]
35. Cross-tolerance between ethanol and neurotensin in mice selectively bred for ethanol sensitivity.
Erwin VG; Campbell AD; Myers R; Womer DE
Pharmacol Biochem Behav; 1995 Aug; 51(4):891-9. PubMed ID: 7675874
[TBL] [Abstract][Full Text] [Related]
36. Recombinant λ bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line.
Shoae-Hassani A; Mortazavi-Tabatabaei SA; Sharif S; Madadi S; Rezaei-Khaligh H; Verdi J
Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):75-83. PubMed ID: 23224340
[TBL] [Abstract][Full Text] [Related]
37. Hypothermia elicited by the intracerebral microinjection of neurotensin.
Martin GE; Bacino CB; Papp NL
Peptides; 1980; 1(4):333-9. PubMed ID: 7301636
[TBL] [Abstract][Full Text] [Related]
38. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.
Dubuc I; Costentin J; Terranova JP; Barnouin MC; Soubrié P; Le Fur G; Rostène W; Kitabgi P
Br J Pharmacol; 1994 Jun; 112(2):352-4. PubMed ID: 8075852
[TBL] [Abstract][Full Text] [Related]
39. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
40. Ontogeny of the hypothermic response to centrally administered neurotensin in rats.
Hernandez DE; Nemeroff CB; Prange AJ
Brain Res; 1982 Mar; 255(3):497-501. PubMed ID: 6896009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
